Alzamend Neuro, Inc. (ALZN) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -193.32%, forward earnings yield 666.67%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2017 | -243.8 | 0.00 | -654.31 | 0.00 | - |
| 2018 | -645.3 | 10.35 | 259.31 | 0.00 | - |
| 2019 | -161.2 | -0.53 | 2,472.82 | 0.00 | - |
| 2020 | -214.9 | 8.56 | 1,153.33 | 0.00 | - |
| 2021 | -191.4 | -15.65 | 479.86 | 0.00 | - |
| 2022 | -7.2 | -0.07 | 6.70 | 0.00 | - |
| 2023 | -3.5 | -0.35 | 16.96 | 0.00 | - |
| 2024 | -0.5 | 0.01 | -1.85 | 0.00 | - |
| 2025 | -0.5 | 0.01 | 0.60 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.42 | $0.00 | $-69.46K | - |
| 2017 | $-8.18 | $0.00 | $-1.57M | - |
| 2018 | $-1.64 | $0.00 | $-932K | - |
| 2019 | $-12.40 | $0.00 | $-4.86M | - |
| 2020 | $-9.25 | $0.00 | $-4.41M | - |
| 2021 | $-0.89 | $0.00 | $-5.05M | - |
| 2022 | $-2.10 | $0.00 | $-12.36M | - |
| 2023 | $-2.25 | $0.00 | $-14.88M | - |
| 2024 | $-14.70 | $0.00 | $-9.95M | - |
| 2025 | $-11.32 | $0.00 | $-4.51M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.52 | $-2.52 – $-2.52 | $0.00 | $0.00 – $0.00 | 1 |
| 2027 | $-2.60 | $-2.60 – $-2.60 | $31.55M | $31.55M – $31.55M | 1 |
| 2028 | $-3.04 | $-3.04 – $-3.04 | $132.71M | $132.71M – $132.71M | 1 |
| 2029 | $-0.86 | $-0.86 – $-0.86 | $32.19M | $32.19M – $32.19M | 1 |
| 2030 | $6.99 | $6.99 – $6.99 | $136.03M | $136.03M – $136.03M | 1 |
